Fennec Pharmaceuticals Inc. (FENC) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Research Triangle Park, NC, United States. El CEO actual es Robert C. Andrade.
FENC tiene fecha de IPO 2017-09-15, 32 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $178.63M.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
